1. Home
  2. GPRK vs EVO Comparison

GPRK vs EVO Comparison

Compare GPRK & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Geopark Ltd

GPRK

Geopark Ltd

HOLD

Current Price

$9.43

Market Cap

706.1M

Sector

Energy

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

BUY

Current Price

$1.57

Market Cap

568.6M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
GPRK
EVO
Founded
2002
1993
Country
Colombia
Germany
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
706.1M
568.6M
IPO Year
2009
2007

Fundamental Metrics

Financial Performance
Metric
GPRK
EVO
Price
$9.43
$1.57
Analyst Decision
Buy
Buy
Analyst Count
4
3
Target Price
★ $11.23
$4.24
AVG Volume (30 Days)
★ 609.6K
72.7K
Earning Date
11-03-2026
11-05-2026
Dividend Yield
★ 0.89%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$18.65
N/A
Revenue Next Year
$33.37
$20.47
P/E Ratio
$12.70
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.84
$1.33
52 Week High
$13.13
$3.87

Technical Indicators

Market Signals
Indicator
GPRK
EVO
Relative Strength Index (RSI) 36.47 49.22
Support Level $10.26 $1.50
Resistance Level $10.60 $1.97
Average True Range (ATR) 0.38 0.04
MACD -0.16 0.02
Stochastic Oscillator 0.62 73.91

Price Performance

Historical Comparison
GPRK
EVO

About GPRK Geopark Ltd

GeoPark Ltd is an independent energy company. Its diversified portfolio of assets consist of Llanos 34 Block in Colombia, CPO-5 Block, Llanos 86, Llanos 87, Llanos 104, Llanos 123, and Llanos 124 Blocks in the Llanos Basin. Its segments include Colombia, Argentina, Brazil and Ecuador, with the majority of the revenue derived from Colombia. It derives revenue from Sale of crude oil, Sale of purchased crude oil, and Sale of gas.

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

Share on Social Networks: